StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a report published on Sunday. The firm issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Performance
The company has a market cap of $45.46 million, a PE ratio of -0.07 and a beta of 1.53. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85. Nabriva Therapeutics has a 12-month low of $1.22 and a 12-month high of $8.45. The stock’s 50 day simple moving average is $0.14.
Nabriva Therapeutics Company Profile
Read More
- Five stocks we like better than Nabriva Therapeutics
- Energy and Oil Stocks Explained
- TJX Companies Can Hit New Highs; Double-Digit Upside to Follow
- 3 Monster Growth Stocks to Buy Now
- A Hidden Gem Retailer With 20% Upside
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Zoom Stock’s Earnings Volatility Picked Up a Lot of Buyers
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.